

REF A11A01740
CONT.

IVD **CE**



HORIBA ABX SAS
Parc Euromédecine
Rue du Caducée
BP 7290
34184 Montpellier Cedex 4
FRANCE

ABX Pentra Potassium-E

■ **ABX Pentra 400**

Ion selective electrode intended for the quantitative determination of potassium in serum, plasma and urine on ISE module (ABX Pentra 400).

Intended Use

ABX Pentra Potassium-E is intended for the quantitative determination of Potassium by potentiometry using ion selective electrode with associated reference solution, calibrators and controls. Measurements of Potassium are used in diagnosis and treatment diseases involving electrolyte imbalance.

Clinical Interest (1)

Electrolytes take part in most of the metabolic functions of the organism. Sodium, potassium and chloride belong to the most important physiological ions and to the more often determined electrolytes. They are basically brought by feeding, absorbed through the digestive tract and excreted by kidneys.

Potassium is the main intracellular cation. It plays a key role in neuromuscular activity.

The decrease of potassium level is sometimes due to a decrease in potassium food supply or an excessive loss of potassium by the organism due to prolonged vomiting or diarrhea or an increase in the renal excretion.

An excessive loss of liquid or a shock, severe burns, diabetic acidocetose or potassium retention by kidneys are the main causes of potassium increase.

The increase of urine potassium level is sometimes due to a start of starvation, a primary or secondary aldosteronism or primary renal diseases (renal tubular syndroms, during the phase of recovery from a severe tubular necrosis, a metabolic acidose or alkalose). We observe as well hyperkaliury with administration of adrenocorticotropic hormones, hydrocortisone and cortisone.

Potassium level decreases with chronic potassic deficiency and renal diseases with urine flow decrease.

The measurement of urine potassium is useful for renal explorations and to study hydroelectric and acid-base balance.

Method

Quantitative determination of potassium with ISE module by potentiometry using ion selective electrode:


- direct (non diluted serum and plasma)
- indirect (diluted urine)

Characteristics

- **ABX Pentra Potassium-E** is packaged individually.
- **ABX Pentra Potassium-E** should be used according to this notice. The manufacturer cannot guarantee its performance if used otherwise.

Handling


1. Before installing an electrode in the instrument, check there is an O-ring.
2. When installing the electrode, place the electrode in the correct position shown below.



- 1: Sample
2: Air sensor

ABX Pentra Potassium-E

3. Make sure that O-rings are placed in the position shown in the drawing below. For the installation of each electrode, take care that the O-ring on the next electrode does not come off.



4. Please refer to the User Manual for electrode installation and maintenance.

Calibrator

For calibration, use:

- ABX Pentra Standard 1** (A11A01717) (not included)
1 x 280 mL
- ABX Pentra Standard 2** (A11A01718) (not included)
1 x 100 mL
- ABX Pentra Reference 280 mL** (A11A01901) (not included)
1 x 280 mL

Control ^a

For internal quality control, use:

- For serum/plasma application only:
 - ABX Pentra N Control / ABX Pentra N MultiControl** (A11A01653 / 1300054414) (not included)
10 x 5 mL (lyophilisate)
 - ABX Pentra P Control / ABX Pentra P MultiControl** (A11A01654 / 1300054415) (not included)
10 x 5 mL (lyophilisate)
- For urine application only:
in progress

Each control should be assayed daily and/or after a calibration.

The frequency of controls and the confidence intervals should correspond to laboratory guidelines and country-specific directives. You should follow federal, state and local guidelines for testing quality control materials. The results must be within the range of the defined confidence limits. Each laboratory should establish a procedure to follow if the results exceed these confidence limits.

Materials Required but not Provided ^a

- Automated clinical chemistry analyzer: ABX Pentra 400 equipped with ISE module option.
- Standard laboratory equipment.
- Electrode: **ABX Pentra Reference-E** (A11A01741).
- Calibrators:
 - ABX Pentra Standard 1** (A11A01717) (not included)
1 x 280 mL
 - ABX Pentra Standard 2** (A11A01718) (not included)
1 x 100 mL
 - ABX Pentra Reference 280 mL** (A11A01901) (not included)
1 x 280 mL
- Controls:
 - ABX Pentra N Control / ABX Pentra N MultiControl** (A11A01653 / 1300054414)
 - ABX Pentra P Control / ABX Pentra P MultiControl** (A11A01654 / 1300054415)

Specimen (2)

- Serum.
- Plasma in lithium heparin.
- Urine.
- Anticoagulants other than those listed have not been tested by HORIBA Medical and are therefore not recommended for use with this assay.
- When using serum as sample, infiltration of potassium from blood cell elements, especially platelets may cause more grave problems than using blood plasma.
- Samples should be separated from the cells promptly after collection. If a sample is stored in a refrigerator without serum separation, a large amount of potassium is infiltrated from red blood cells.
- Use centrifuged urine samples.
- The serum or plasma separation must be done immediately or before 24 hours if the sample is stored in a closed tube (3).

Electrolyte stability in samples stored in airtight tubes (3) (after separation):

	15-25°C	4°C	-20°C
Potassium in serum/plasma:	14 days	14 days	stable
Potassium in urine:	14 days	N/A	N/A

^aModification: new control.

ABX Pentra Potassium-E

Reference Range (1)

Each laboratory should establish its own reference ranges. The values given here are used as guidelines only.

Serum:

Adults 3.7-5.5 mmol/L

Plasma:

Adults 3.6-4.8 mmol/L

Urine:

Adults 25 - 125 mmol/24h

Storage and Stability

The unopened electrodes may be installed up to the date mentioned on the packaging label if stored at 15-35°C. Once installed on the ISE module, Potassium electrode can be used for 6 months.

Waste Management

Please refer to local legal requirements.

General Precautions

- This electrode is for professional *in vitro* diagnostic use only.
- For prescription use only.
- This product is classified as non-hazardous in compliance with regulation (EC) N°.1272/2008.
- Observe the standard laboratory precautions for use.
- Operate the instrument according to User Manual under appropriate conditions.
- Wear rubber gloves during a replacement of electrodes.
- Please refer to the SDS associated with the electrode.
- Do not use the product if there is visible evidence of biological, chemical or physical deterioration.
- It is the user's responsibility to verify that this document is applicable to the electrode used.

Performance on ABX Pentra 400

Sample Volume

Serum/Plasma: 60 µL/test 1, 2 or 3 electrolytes
Urine: 20 µL/test 1, 2 or 3 electrolytes

Accuracy and Precision

Repeatability (within-run precision)

2 control levels were tested in 2 runs, 20 times per run, according to the recommendations found in the Valtec protocol (4).

	Mean value mmol/L	CV %
Normal control	3.75	0.29
	3.81	0.64
Pathological control	6.81	0.65
	6.86	0.49

2 serum specimens, 2 plasma specimens and 2 urine specimens were tested 10 times, according to the recommendations found in the Valtec protocol (4).

	Mean value mmol/L	CV %
Serum specimen 1	4.14	0.47
Serum specimen 2	4.99	0.42
Plasma specimen 1	4.35	0.46
Plasma specimen 2	4.26	0.40
Urine specimen 1	45.40	1.67
Urine specimen 2	67.32	1.51

Reproducibility (total precision)

2 controls were tested in duplicate for 20 days (2 series per day) according to the recommendations found in the CLSI (NCCLS), EP5-A protocol (5).

	Mean value mmol/L	CV %
Control specimen 1	3.82	1.28
Control specimen 2	6.76	1.56

Linearity and Measuring Range

The measuring range of the assay is:
For serum and plasma: from 1.4 to 10 mmol/L.
For urine: from 2 to 150 mmol/L.

The linearity has been assessed on the measuring range according to the recommendations found in the CLSI (NCCLS), EP6-A protocol (6).

Correlation ^b

All the performance data listed below have been obtained on the ABX Pentra 400 analyser using the following factors:

^bModification: modification of correlation.

ABX Pentra Potassium-E

Serum/Plasma: $y = 1.18 x - 0.4$ (mmol/L)

Urine: $y = 1.25 x - 1$ (mmol/L)

x = ABX Pentra 400 raw values.

These factors have been obtained by comparing with MIRA Plus analyser (direct method).

N patient samples are correlated with the Mira Plus taken as reference according to the recommendations found in the CLSI (NCCLS), EP9-A2 protocol (7).

The equation for the allometric line obtained on serum (N=100) using Passing-Bablok regression procedure (8) is:

$$Y = 1.00 X + 0.00 \text{ with a correlation coefficient } r^2 = 1.$$

The equation for the allometric line obtained on plasma (N=100) using Passing-Bablok regression procedure (8) is:

$$Y = 1.00 X + 0.00 \text{ with a correlation coefficient } r^2 = 1.$$

The equation for the allometric line obtained on urine (N=103) using Passing-Bablok regression procedure (8) is:

$$Y = 1.03 X - 0.72 \text{ with a correlation coefficient } r^2 = 0.99.$$

Interferences (9, 10)

Interferences in serum/plasma °

Haemoglobin:	No significant influence is observed up to 1 g/L.
Triglycerides:	No significant influence.
Total Bilirubin:	No significant influence.
Direct Bilirubin:	No significant influence.
Probenecid:	No significant influence is observed up to 1370 µmol/L.
Valproic Acid:	No significant influence is observed up to 303.6 µg/mL.

Other limitations are given by Young as a list of drugs and preanalytical variables known to affect this methodology (11, 12).

Calibration Stability

A one point calibration is made automatically every 15 minutes.

A two point calibration is made automatically every 120 minutes.

Reference

1. Scott MG, LeGrys VA, Klutts JS. Electrolytes and Blood Gases. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnosis. 4th ed. St Louis, Missouri: Elsevier Saunders (2006): 983-990.
2. Kanai I, Kanai M, Rinshokensaho-teiyo, revised, 30th edition, Kanehara-syuppan, Tokyo (1993): VIII709.
3. Young DS. Storage of specimen. In: Effects of Preanalytical Variables on Clinical Laboratory Tests. 1st ed. Washington: AACC Press (1993): 4-269 - 4-278.
4. Vassault A, Grafmeyer D, Naudin C et al. Protocole de validation de techniques (document B). Ann. Biol. Clin. (1986) **44**: 686-745.
5. Evaluation of Precision Performance of Clinical Chemistry Devices. Approved Guideline, CLSI (NCCLS) document EP5-A (1999) **19** (2).
6. Evaluation of the Linearity of Quantitative Analytical Methods. Approved Guideline, CLSI (NCCLS) document EP6-A (2003) **23** (16).
7. Method Comparison and Bias Estimation Using Patient Samples. Approved Guideline, 2nd ed., CLSI (NCCLS) document EP9-A2 (2002) **22** (19).
8. Passing H, Bablock W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. J. Clin. Chem. Clin. Biochem. (1983) **21**: 709-20.
9. Vlatko Rumenjak, Stjepan Milardovic, Ivan Kryhak. The study of some possible measurement errors in clinical blood electrolyte potentiometric (ISE) analyzers. Clinica Chimica Acta (2003) **335**: 75-81.
10. Malinowska E, Meyerhoff M. Influence of Nonionic Surfactants on the Potentiometric Response of Ion-Selective polymeric Membrane Electrodes Designed for Blood Electrolyte Measurement.
11. Young DS. Effects of Drugs on Clinical Laboratory Tests. 4th Edition, Washington, DC, AACC Press (1997) **3**: 143-163.
12. Young DS. Effects of Preanalytical Variables on Clinical Laboratory Tests. 2nd Edition, Washington, DC, AACC Press (1997) **3**: 120-132.

°Modification: modification of interferences.